Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.60), $0.02 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.